Literature DB >> 24317392

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Maryline Allegra1, Damien Giacchero2, Coralie Segalen3, Nicolas Dumaz4, Catherine Butori5, Véronique Hofman6, Paul Hofman6, Jean-Philippe Lacour7, Corine Bertolotto8, Philippe Bahadoran9, Robert Ballotti10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24317392     DOI： 10.1038/jid.2013.525

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  18 in total

1.  Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Adrian Marino-Enriquez; Ajia Presnell; Rachel S Donsky; Diana J Griffith; Arin McKinley; Janice Patterson; Takahiro Taguchi; Cher-Wei Liang; Jonathan A Fletcher
Journal:  Mol Cancer Ther       Date:  2012-06-04       Impact factor: 6.261

2.  Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes.

Authors:  Vitali Alexeev; Kyonggeun Yoon
Journal:  J Invest Dermatol       Date:  2006-05       Impact factor: 8.551

3.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

6.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

7.  The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.

Authors:  Ruixia Liang; Andrea R Wallace; Dirk Schadendorf; Brian P Rubin
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-10       Impact factor: 4.693

8.  KIT gene mutations and copy number in melanoma subtypes.

Authors:  Carol Beadling; Erick Jacobson-Dunlop; F Stephen Hodi; Claudia Le; Andrea Warrick; Janice Patterson; Ajia Town; Amy Harlow; Frank Cruz; Sharl Azar; Brian P Rubin; Susan Muller; Rob West; Michael C Heinrich; Christopher L Corless
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

9.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Authors:  D Handolias; A L Hamilton; R Salemi; A Tan; K Moodie; L Kerr; A Dobrovic; G A McArthur
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

10.  Oncogenic activating mutations are associated with local copy gain.

Authors:  Barmak Modrek; Lin Ge; Ajay Pandita; Eva Lin; Sankar Mohan; Peng Yue; Steve Guerrero; William M Lin; Thinh Pham; Zora Modrusan; Somasekar Seshagiri; Howard M Stern; Paul Waring; Levi A Garraway; John Chant; David Stokoe; Guy Cavet
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852
View more
  2 in total

Review 1.  Focus on cutaneous and uveal melanoma specificities.

Authors:  Charlotte Pandiani; Guillaume E Béranger; Justine Leclerc; Robert Ballotti; Corine Bertolotto
Journal:  Genes Dev       Date:  2017-04-15       Impact factor: 11.361

Review 2.  Aspects of Modern Biobank Activity - Comprehensive Review.

Authors:  Wiktor Paskal; Adriana M Paskal; Tomasz Dębski; Maciej Gryziak; Janusz Jaworowski
Journal:  Pathol Oncol Res       Date:  2018-05-05       Impact factor: 3.201
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.